Published in Antimicrob Agents Chemother on May 04, 2009
Cryptococcus neoformans overcomes stress of azole drugs by formation of disomy in specific multiple chromosomes. PLoS Pathog (2010) 2.04
Regulatory circuitry governing fungal development, drug resistance, and disease. Microbiol Mol Biol Rev (2011) 1.90
Cryptococcus gattii infections. Clin Microbiol Rev (2014) 1.55
Heteroresistance of Cryptococcus gattii to fluconazole. Antimicrob Agents Chemother (2010) 1.26
Cryptococcus neoformans and Cryptococcus gattii, the etiologic agents of cryptococcosis. Cold Spring Harb Perspect Med (2014) 1.18
Identification of a Cryptococcus neoformans cytochrome P450 lanosterol 14α-demethylase (Erg11) residue critical for differential susceptibility between fluconazole/voriconazole and itraconazole/posaconazole. Antimicrob Agents Chemother (2011) 1.16
Contribution of CgPDR1-regulated genes in enhanced virulence of azole-resistant Candida glabrata. PLoS One (2011) 1.13
TLR9 signaling is required for generation of the adaptive immune protection in Cryptococcus neoformans-infected lungs. Am J Pathol (2010) 1.06
Deletion of Cryptococcus neoformans AIF ortholog promotes chromosome aneuploidy and fluconazole-resistance in a metacaspase-independent manner. PLoS Pathog (2011) 1.03
Aneuploidy and drug resistance in pathogenic fungi. PLoS Pathog (2012) 0.98
Cryptococcosis: epidemiology, fungal resistance, and new alternatives for treatment. Eur J Clin Microbiol Infect Dis (2013) 0.97
Azole heteroresistance in Cryptococcus neoformans: emergence of resistant clones with chromosomal disomy in the mouse brain during fluconazole treatment. Antimicrob Agents Chemother (2013) 0.95
Genome-wide expression profiling of the response to short-term exposure to fluconazole in Cryptococcus neoformans serotype A. BMC Microbiol (2011) 0.91
Correlation of anti-fungal susceptibility with clinical outcomes in patients with cryptococcal meningitis. BMC Infect Dis (2012) 0.90
Yeast: a simple model system to study complex phenomena of aneuploidy. FEMS Microbiol Rev (2013) 0.88
Rapid mechanisms for generating genome diversity: whole ploidy shifts, aneuploidy, and loss of heterozygosity. Cold Spring Harb Perspect Med (2014) 0.87
Involvement of PDK1, PKC and TOR signalling pathways in basal fluconazole tolerance in Cryptococcus neoformans. Mol Microbiol (2012) 0.87
Characterization of the chromosome 4 genes that affect fluconazole-induced disomy formation in Cryptococcus neoformans. PLoS One (2012) 0.87
Multilocus sequence typing of serially collected isolates of Cryptococcus from HIV-infected patients in South Africa. J Clin Microbiol (2014) 0.85
Cryptococcus: from environmental saprophyte to global pathogen. Nat Rev Microbiol (2015) 0.85
Fluconazole alters the polysaccharide capsule of Cryptococcus gattii and leads to distinct behaviors in murine Cryptococcosis. PLoS One (2014) 0.84
Balancing stability and flexibility within the genome of the pathogen Cryptococcus neoformans. PLoS Pathog (2013) 0.80
Impact of Resistance to Fluconazole on Virulence and Morphological Aspects of Cryptococcus neoformans and Cryptococcus gattii Isolates. Front Microbiol (2016) 0.79
Cryptococcus neoformans Yop1 , an endoplasmic reticulum curvature-stabilizing protein, participates with Sey1 in influencing fluconazole-induced disomy formation. FEMS Yeast Res (2012) 0.78
Cryptococcus neoformans Yap1 is required for normal fluconazole and oxidative stress resistance. Fungal Genet Biol (2014) 0.78
Clinical significance of the isolation of Candida species from hospitalized patients. Braz J Microbiol (2015) 0.78
Large-Scale Chromosomal Changes and Associated Fitness Consequences in Pathogenic Fungi. Curr Fungal Infect Rep (2014) 0.77
Ploidy dynamics and evolvability in fungi. Philos Trans R Soc Lond B Biol Sci (2016) 0.77
Antifolates inhibit Cryptococcus biofilms and enhance susceptibility of planktonic cells to amphotericin B. Eur J Clin Microbiol Infect Dis (2012) 0.77
Gene Function Analysis in the Ubiquitous Human Commensal and Pathogen Malassezia Genus. MBio (2016) 0.75
Heteroresistance to Itraconazole Alters the Morphology and Increases the Virulence of Cryptococcus gattii. Antimicrob Agents Chemother (2015) 0.75
Identification of QTLs Associated with Virulence Related Traits and Drug Resistance in Cryptococcus neoformans. G3 (Bethesda) (2016) 0.75
Retrospective Study of Cryptococcal Meningitis With Elevated Minimum Inhibitory Concentration to Fluconazole in Immunocompromised Patients. Open Forum Infect Dis (2016) 0.75
Abdominal Lymphonodular Cryptococcosis in an Immunocompetent Child. Case Rep Pediatr (2015) 0.75
Fluconazole Susceptibility in Cryptococcus gattii Is Dependent on the ABC Transporter Pdr11. Antimicrob Agents Chemother (2015) 0.75
Molecular characterisation and antifungal susceptibility of clinical Cryptococcus deuterogattii (AFLP6/VGII) isolates from Southern Brazil. Eur J Clin Microbiol Infect Dis (2016) 0.75
Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother (1995) 7.44
Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C). J Clin Microbiol (1982) 6.78
Gene transfer in Cryptococcus neoformans by use of biolistic delivery of DNA. J Bacteriol (1993) 5.14
Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science (2005) 5.04
Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother (1997) 4.75
The genome of the basidiomycetous yeast and human pathogen Cryptococcus neoformans. Science (2005) 4.74
Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis (2002) 4.56
Aneuploidy and isochromosome formation in drug-resistant Candida albicans. Science (2006) 4.09
Resistance mechanisms in clinical isolates of Candida albicans. Antimicrob Agents Chemother (2002) 3.38
Cryptococcus neoformans interactions with amoebae suggest an explanation for its virulence and intracellular pathogenic strategy in macrophages. Proc Natl Acad Sci U S A (2001) 3.37
Contribution of mutations in the cytochrome P450 14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. Microbiology (1999) 3.19
A point mutation in the 14alpha-sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother (2003) 3.17
Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis (1990) 3.02
Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. Clin Infect Dis (2006) 2.76
Molecular basis of resistance to azole antifungals. Trends Mol Med (2002) 2.48
Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia. Antimicrob Agents Chemother (1997) 2.43
An isochromosome confers drug resistance in vivo by amplification of two genes, ERG11 and TAC1. Mol Microbiol (2008) 2.34
Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR. Antimicrob Agents Chemother (1998) 2.15
Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis. Antimicrob Agents Chemother (2004) 2.09
Genetic architecture of Hsp90-dependent drug resistance. Eukaryot Cell (2006) 2.09
Correlation of in vitro azole susceptibility with in vivo response in a murine model of cryptococcal meningitis. J Infect Dis (1993) 2.03
Stable azole drug resistance associated with a substrain of Candida albicans from an HIV-infected patient. Oral Dis (1997) 2.00
Increased fluconazole resistance of Cryptococcus neoformans isolated from a patient with AIDS and recurrent meningitis. Clin Infect Dis (1994) 1.87
Role of Candida albicans transcription factor Upc2p in drug resistance and sterol metabolism. Eukaryot Cell (2004) 1.87
Development of fluconazole resistance in Candida albicans causing disseminated infection in a patient undergoing marrow transplantation. Clin Infect Dis (1997) 1.84
Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance. Eukaryot Cell (2008) 1.73
Candida glabrata PDR1, a transcriptional regulator of a pleiotropic drug resistance network, mediates azole resistance in clinical isolates and petite mutants. Antimicrob Agents Chemother (2006) 1.70
Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998. Antimicrob Agents Chemother (2001) 1.70
Molecular subtypes and antifungal susceptibilities of serial Cryptococcus neoformans isolates in human immunodeficiency virus-associated Cryptococcosis. Cryptococcal Disease Active Surveillance Group. J Infect Dis (1996) 1.67
Evolution of drug resistance in Candida albicans. Annu Rev Microbiol (2002) 1.67
Resistance of human fungal pathogens to antifungal drugs. Curr Opin Microbiol (2002) 1.65
In vitro evolution of itraconazole resistance in Aspergillus fumigatus involves multiple mechanisms of resistance. Antimicrob Agents Chemother (2004) 1.62
The hidden danger of primary fluconazole prophylaxis for patients with AIDS. Clin Infect Dis (1998) 1.60
Inducible azole resistance associated with a heterogeneous phenotype in Candida albicans. Antimicrob Agents Chemother (2001) 1.58
Reversible fluconazole resistance in Candida albicans: a potential in vitro model. Antimicrob Agents Chemother (1997) 1.54
Correlation of fluconazole MICs with clinical outcome in cryptococcal infection. Antimicrob Agents Chemother (2000) 1.51
Capsule enlargement in Cryptococcus neoformans confers resistance to oxidative stress suggesting a mechanism for intracellular survival. Cell Microbiol (2008) 1.50
Multiple resistance mechanisms to azole antifungals in yeast clinical isolates. Drug Resist Updat (1998) 1.40
Heteroresistance to fluconazole and voriconazole in Cryptococcus neoformans. Antimicrob Agents Chemother (1999) 1.38
Mechanisms of azole resistance in petite mutants of Candida glabrata. Antimicrob Agents Chemother (2004) 1.37
Possible development of resistance to fluconazole during suppressive therapy for AIDS-associated cryptococcal meningitis. Clin Infect Dis (1996) 1.35
G484S amino acid substitution in lanosterol 14-alpha demethylase (ERG11) is related to fluconazole resistance in a recurrent Cryptococcus neoformans clinical isolate. Antimicrob Agents Chemother (2003) 1.28
Identification and characterization of a Cryptococcus neoformans ATP binding cassette (ABC) transporter-encoding gene, CnAFR1, involved in the resistance to fluconazole. Mol Microbiol (2003) 1.25
In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans. Antimicrob Agents Chemother (2000) 1.23
Fluconazole tolerance in clinical isolates of Cryptococcus neoformans. Antimicrob Agents Chemother (1997) 1.23
Cross-resistance to polyene and azole drugs in Cryptococcus neoformans. Antimicrob Agents Chemother (1995) 1.23
Development of azole resistance during fluconazole maintenance therapy for AIDS-associated cryptococcal disease. AIDS (2001) 1.17
Candida glabrata erg1 mutant with increased sensitivity to azoles and to low oxygen tension. Antimicrob Agents Chemother (2004) 1.05
Sterol 24-C-methyltransferase: an enzymatic target for the disruption of ergosterol biosynthesis and homeostasis in Cryptococcus neoformans. Arch Biochem Biophys (2008) 0.98
Characterization of heteroresistance to fluconazole among clinical isolates of Cryptococcus neoformans. J Clin Microbiol (2003) 0.97
Roles of cellular respiration, CgCDR1, and CgCDR2 in Candida glabrata resistance to histatin 5. Antimicrob Agents Chemother (2006) 0.91
Dynamic and heterogeneous mutations to fluconazole resistance in Cryptococcus neoformans. Antimicrob Agents Chemother (2001) 0.91
Fluconazole: comparison of pharmacokinetics, therapy and in vitro susceptibility. Mycoses (1997) 0.86
Cryptococcosis. J Int Assoc Physicians AIDS Care (1996) 0.82
Canavanine resistance in Cryptococcus neoformans. Antimicrob Agents Chemother (1986) 0.82
Alkaloids from amphibian skin: a tabulation of over eight-hundred compounds. J Nat Prod (2005) 3.02
Human polymorphonuclear leukocytes inhibit Aspergillus fumigatus conidial growth by lactoferrin-mediated iron depletion. J Immunol (2007) 2.05
Cryptococcus neoformans overcomes stress of azole drugs by formation of disomy in specific multiple chromosomes. PLoS Pathog (2010) 2.04
Cryptococcal yeast cells invade the central nervous system via transcellular penetration of the blood-brain barrier. Infect Immun (2004) 1.99
Sre1p, a regulator of oxygen sensing and sterol homeostasis, is required for virulence in Cryptococcus neoformans. Mol Microbiol (2007) 1.93
Cryptococcus neoformans strains and infection in apparently immunocompetent patients, China. Emerg Infect Dis (2008) 1.72
Invasive aspergillosis due to Neosartorya udagawae. Clin Infect Dis (2009) 1.70
Gliotoxin is a virulence factor of Aspergillus fumigatus: gliP deletion attenuates virulence in mice immunosuppressed with hydrocortisone. Eukaryot Cell (2007) 1.69
Complementation of a capsule deficient Cryptococcus neoformans with CAP64 restores virulence in a murine lung infection. Am J Respir Cell Mol Biol (2002) 1.65
Cryptococcus neoformans CAP59 (or Cap59p) is involved in the extracellular trafficking of capsular glucuronoxylomannan. Eukaryot Cell (2004) 1.64
Oribatid mites as a major dietary source for alkaloids in poison frogs. Proc Natl Acad Sci U S A (2007) 1.41
Role of laeA in the Regulation of alb1, gliP, Conidial Morphology, and Virulence in Aspergillus fumigatus. Eukaryot Cell (2007) 1.41
Formicine ants: An arthropod source for the pumiliotoxin alkaloids of dendrobatid poison frogs. Proc Natl Acad Sci U S A (2004) 1.39
Bioactive alkaloids of frog skin: combinatorial bioprospecting reveals that pumiliotoxins have an arthropod source. Proc Natl Acad Sci U S A (2002) 1.35
Genes differentially expressed in conidia and hyphae of Aspergillus fumigatus upon exposure to human neutrophils. PLoS One (2008) 1.34
Agrobacterium tumefaciens-mediated transformation of Aspergillus fumigatus: an efficient tool for insertional mutagenesis and targeted gene disruption. Appl Environ Microbiol (2005) 1.33
Prevalence of the VNIc genotype of Cryptococcus neoformans in non-HIV-associated cryptococcosis in the Republic of Korea. FEMS Yeast Res (2010) 1.32
Evidence for an enantioselective pumiliotoxin 7-hydroxylase in dendrobatid poison frogs of the genus Dendrobates. Proc Natl Acad Sci U S A (2003) 1.31
Involvement of human CD44 during Cryptococcus neoformans infection of brain microvascular endothelial cells. Cell Microbiol (2008) 1.27
Hydrolytic polyketide shortening by ayg1p, a novel enzyme involved in fungal melanin biosynthesis. J Biol Chem (2004) 1.23
The primary target organ of Cryptococcus gattii is different from that of Cryptococcus neoformans in a murine model. MBio (2012) 1.22
Uniqueness of the mating system in Cryptococcus neoformans. Trends Microbiol (2004) 1.22
Aspergillus fumigatus conidial melanin modulates host cytokine response. Immunobiology (2009) 1.21
Cas3p belongs to a seven-member family of capsule structure designer proteins. Eukaryot Cell (2004) 1.19
Cobalt chloride, a hypoxia-mimicking agent, targets sterol synthesis in the pathogenic fungus Cryptococcus neoformans. Mol Microbiol (2007) 1.17
Identification of a Cryptococcus neoformans cytochrome P450 lanosterol 14α-demethylase (Erg11) residue critical for differential susceptibility between fluconazole/voriconazole and itraconazole/posaconazole. Antimicrob Agents Chemother (2011) 1.16
Identification and characterization of CPS1 as a hyaluronic acid synthase contributing to the pathogenesis of Cryptococcus neoformans infection. Eukaryot Cell (2007) 1.11
Cryptococcus neoformans Site-2 protease is required for virulence and survival in the presence of azole drugs. Mol Microbiol (2009) 1.11
Cloning and functional characterization of the Rhizopus oryzae high affinity iron permease (rFTR1) gene. FEMS Microbiol Lett (2004) 1.11
Indolizidine 239Q and quinolizidine 275I. Major alkaloids in two Argentinian bufonid toads (Melanophryniscus). Toxicon (2008) 1.09
Geographic and seasonal variation in alkaloid-based chemical defenses of Dendrobates pumilio from Bocas del Toro, Panama. J Chem Ecol (2006) 1.05
Invasion of Cryptococcus neoformans into human brain microvascular endothelial cells requires protein kinase C-alpha activation. Cell Microbiol (2008) 1.05
High frequency transformation of Cryptococcus neoformans and Cryptococcus gattii by Agrobacterium tumefaciens. Fungal Genet Biol (2005) 1.04
Identification and characterization of an Aspergillus fumigatus "supermater" pair. MBio (2011) 1.04
Importance of mitochondria in survival of Cryptococcus neoformans under low oxygen conditions and tolerance to cobalt chloride. PLoS Pathog (2008) 1.04
Molecular analysis of CPRalpha, a MATalpha-specific pheromone receptor gene of Cryptococcus neoformans. Eukaryot Cell (2002) 1.04
Invasion of Cryptococcus neoformans into human brain microvascular endothelial cells is mediated through the lipid rafts-endocytic pathway via the dual specificity tyrosine phosphorylation-regulated kinase 3 (DYRK3). J Biol Chem (2011) 1.04
Biologically active substances from amphibians: preliminary studies on anurans from twenty-one genera of Thailand. Toxicon (2004) 1.03
Regulatory diversity of TUP1 in Cryptococcus neoformans. Eukaryot Cell (2009) 1.03
Aspergillus tanneri sp. nov., a new pathogen that causes invasive disease refractory to antifungal therapy. J Clin Microbiol (2012) 0.99
Hyaluronic acid receptor CD44 deficiency is associated with decreased Cryptococcus neoformans brain infection. J Biol Chem (2012) 0.99
Conservation of the sterol regulatory element-binding protein pathway and its pathobiological importance in Cryptococcus neoformans. Eukaryot Cell (2009) 0.98
Aneuploidy and drug resistance in pathogenic fungi. PLoS Pathog (2012) 0.98
Cryptotrichosporon anacardii gen. nov., sp. nov., a new trichosporonoid capsulate basidiomycetous yeast from Nigeria that is able to form melanin on niger seed agar. FEMS Yeast Res (2006) 0.97
TUP1 disruption in Cryptococcus neoformans uncovers a peptide-mediated density-dependent growth phenomenon that mimics quorum sensing. Mol Microbiol (2007) 0.96
Epiquinamide: a poison that wasn't from a frog that was. J Nat Prod (2009) 0.96
Bacterial endosymbiosis is widely present among zygomycetes but does not contribute to the pathogenesis of mucormycosis. J Infect Dis (2008) 0.95
Azole heteroresistance in Cryptococcus neoformans: emergence of resistant clones with chromosomal disomy in the mouse brain during fluconazole treatment. Antimicrob Agents Chemother (2013) 0.95
Bioassay-guided isolation of epiquinamide, a novel quinolizidine alkaloid and nicotinic agonist from an Ecuadoran poison frog, Epipedobates tricolor. J Nat Prod (2003) 0.94
Synthesis of alkaloid 223A and a structural revision. Org Lett (2002) 0.94
Sex-related differences in alkaloid chemical defenses of the dendrobatid frog Oophaga pumilio from Cayo Nancy, Bocas del Toro, Panama. J Nat Prod (2010) 0.91
TUP1 disruption reveals biological differences between MATa and MATalpha strains of Cryptococcus neoformans. Mol Microbiol (2005) 0.91
Cryptococcus neoformans phospholipase B1 activates host cell Rac1 for traversal across the blood-brain barrier. Cell Microbiol (2012) 0.90
Identification of a novel gene, URE2, that functionally complements a urease-negative clinical strain of Cryptococcus neoformans. Microbiology (2006) 0.90
Invasive infection with Trichosporon inkin in 2 siblings with chronic granulomatous disease. J Allergy Clin Immunol (2004) 0.89
Factors required for activation of urease as a virulence determinant in Cryptococcus neoformans. MBio (2013) 0.88
Characterization of the chromosome 4 genes that affect fluconazole-induced disomy formation in Cryptococcus neoformans. PLoS One (2012) 0.87
Venom chemistry of the ant Myrmicaria melanogaster from Brunei. J Nat Prod (2007) 0.87
Cryptococcus neoformans-derived microvesicles enhance the pathogenesis of fungal brain infection. PLoS One (2012) 0.87
Involvement of PDK1, PKC and TOR signalling pathways in basal fluconazole tolerance in Cryptococcus neoformans. Mol Microbiol (2012) 0.87
Differences in nitrogen metabolism between Cryptococcus neoformans and C. gattii, the two etiologic agents of cryptococcosis. PLoS One (2012) 0.87
Human leukocytes kill Aspergillus nidulans by reactive oxygen species-independent mechanisms. Infect Immun (2010) 0.86
Cryptococcus neoformans with a mutation in the tetratricopeptide repeat-containing gene, CCN1, causes subcutaneous lesions but fails to cause systemic infection. Infect Immun (2003) 0.86
Olfm4 deletion enhances defense against Staphylococcus aureus in chronic granulomatous disease. J Clin Invest (2013) 0.86
Flexible synthetic routes to poison-frog alkaloids of the 5,8-disubstituted indolizidine-class I: synthesis of common lactam chiral building blocks and application to the synthesis of (-)-203A, (-)-205A, and (-)-219F. Beilstein J Org Chem (2007) 0.85
Synthesis of poison-frog alkaloids 233A, 235U, and 251AA and their inhibitory effects on neuronal nicotinic acetylcholine receptors. Bioorg Med Chem Lett (2007) 0.84
Flexible synthesis of poison-frog alkaloids of the 5,8-disubstituted indolizidine-class. II: Synthesis of (-)-209B, (-)-231C, (-)-233D, (-)-235B", (-)-221I, and an epimer of 193E and pharmacological effects at neuronal nicotinic acetylcholine receptors. Beilstein J Org Chem (2007) 0.84
Chloroquine modulates the fungal immune response in phagocytic cells from patients with chronic granulomatous disease. J Infect Dis (2013) 0.84
Cryptococcus neoformans activates RhoGTPase proteins followed by protein kinase C, focal adhesion kinase, and ezrin to promote traversal across the blood-brain barrier. J Biol Chem (2012) 0.84
Individual and geographic variation of skin alkaloids in three species of Madagascan poison frogs (Mantella). J Chem Ecol (2008) 0.83
Phantasmidine: an epibatidine congener from the ecuadorian poison frog Epipedobates anthonyi. J Nat Prod (2010) 0.82